ZNTL (Zentalis Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ZNTL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | WALTERS GROUP | 10%+ Owner | Buy | — | — |
| 2026-06-18 | Enoch Kariuki | Director | A | — | — |
| 2026-06-18 | Luke Nathaniel Walker | Director | A | — | — |
| 2026-06-18 | Jan Skvarka | Director | A | — | — |
| 2026-06-18 | Scott Dunseth Myers | Director | A | — | — |
| 2026-06-18 | David Michael Johnson | Director | A | — | — |
| 2026-05-27 | Shannon Campbell | Director | A | — | — |
| 2026-02-10 | JULIA MARIE EASTLAND | CEO & President | Sell | — | — |
| 2026-02-10 | Vincent Vultaggio | PAO and PFO | Sell | — | — |
| 2026-02-10 | Ingmar Bruns | Chief Medical Officer | Sell | — | — |
| 2026-02-04 | Vincent Vultaggio | PAO and PFO | Sell | — | — |
| 2026-01-09 | James B Bucher | Chief Legal Officer | A | — | — |
| 2026-01-09 | JULIA MARIE EASTLAND | CEO & President | A | — | — |
| 2026-01-09 | Vincent Vultaggio | PAO and PFO | A | — | — |
| 2026-01-09 | Ingmar Bruns | Chief Medical Officer | A | — | — |
| 2026-01-08 | WILLIAM THURMAN WALTERS | 10%+ Owner | Buy | — | — |
| 2025-12-15 | DAVID E. GOEL | 10%+ Owner | Sell | — | — |
| 2025-10-01 | James B Bucher | Chief Legal Officer | A | — | — |
| 2025-06-18 | Scott Dunseth Myers | Director | A | — | — |
| 2025-06-18 | Jan Skvarka | Director | A | — | — |
| 2025-06-18 | Luke Nathaniel Walker | Director | A | — | — |
| 2025-06-18 | David Michael Johnson | Director | A | — | — |
| 2025-06-18 | Enoch Kariuki | Director | A | — | — |
| 2025-04-30 | Scott Dunseth Myers | Director | Buy | — | — |
| 2025-02-12 | Ingmar Bruns | Chief Medical Officer | Buy | — | — |
| 2025-02-05 | Ingmar Bruns | Chief Medical Officer | A | — | — |
| 2025-02-05 | Andrea Paul | Chief Legal Officer | MIXED | — | — |
| 2025-02-05 | JULIA MARIE EASTLAND | CEO & President | A | — | — |
| 2025-02-05 | Mark Lackner | Chief Scientific Officer | MIXED | — | — |
| 2025-02-05 | Vincent Vultaggio | PAO and Interim PFO | MIXED | — | — |
| 2025-02-04 | Luke Nathaniel Walker | Director | Buy | — | — |
| 2025-02-04 | Jan Skvarka | Director | Buy | — | — |
| 2025-02-04 | JULIA MARIE EASTLAND | CEO & President | Buy | — | — |
| 2025-01-03 | Mark Lackner | Chief Scientific Officer | Sell | — | — |
| 2024-12-03 | JULIA MARIE EASTLAND | CEO & President | A | — | — |
| 2024-12-03 | Ingmar Bruns | Chief Medical Officer | A | — | — |
| 2024-11-13 | Scott Dunseth Myers | Director | A | — | — |
| 2024-10-04 | Vincent Vultaggio | Principal Accounting Officer | Sell | — | — |
| 2024-06-21 | Enoch Kariuki | Director | A | — | — |
| 2024-06-21 | David Michael Johnson | Director | A | — | — |
| 2024-06-21 | Jan Skvarka | Director | A | — | — |
| 2024-05-31 | Cam Gallagher | President, Interim CFO | Sell | — | — |
| 2024-05-29 | Luke Nathaniel Walker | Director | A | — | — |
| 2024-05-09 | DIANA HAUSMAN | Chief Medical Officer | Sell | — | — |
| 2024-02-12 | Epperly Melissa B, | Chief Financial Officer | Sell | — | — |
| 2024-02-12 | Cam Gallagher | President | Sell | — | — |
| 2024-02-05 | DIANA HAUSMAN | Chief Medical Officer | A | — | — |
| 2024-02-05 | Epperly Melissa B, | Chief Financial Officer | MIXED | — | — |
| 2024-02-05 | Cam Gallagher | President | MIXED | — | — |
| 2024-02-05 | Mark Lackner | Chief Scientific Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 17,844,973 | — |
| — | 10%+ Owner | 13,509,973 | — |
| — | 10%+ Owner | 6,459,973 | — |
| — | 10%+ Owner | 4,443,284 | — |
| — | 10%+ Owner | 3,943,284 | — |
| — | President & CEO | 1,389,189 | — |
| — | Chief Legal Officer | 1,070,784 | — |
| — | Chief Scientific Officer | 849,931 | — |
| — | President, Interim CFO | 636,753 | — |
| — | Chief Scientific Officer | 527,224 | — |
| — | Chief Executive Officer | 484,145 | — |
| — | Chief Financial Officer | 451,449 | — |
| — | Director | 395,895 | — |
| — | Chief Medical Officer | 373,876 | — |
| — | Director | 307,521 | — |
| — | Director | 264,254 | — |
| — | Director | 201,384 | — |
| — | Director | 194,465 | — |
| — | PAO and PFO | 156,779 | — |
| — | Director | 114,200 | — |
| — | Chief Medical Officer | 107,407 | — |
| — | CEO & President | 80,022 | — |
| — | Chief Operating Officer | 52,500 | — |
| — | Chief Medical Officer | 33,667 | — |
| — | Chief Legal Officer | 22,931 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ZNTL quote page; the site-wide leaderboard is on the insider transactions hub.